Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Medical Devices

MONOLISA™ Anti-HBc EIA - P060031

Photo of MONOLISA™ Anti-HBc EIA - P060031This is a brief overview of information related to FDA's approval to market this product. See the links below to the Summary of Safety and Effectiveness and product labeling for more complete information on this product, its indications for use, and the basis for FDA's approval.

Product Name: MONOLISA™ Anti-HBc EIA
PMA Applicant: Bio-Rad Laboratories
Address: 6565 185th Ave NE, Redmond WA 98052
Approval Date: April 27, 2007
Approval Letter:

What is it? The MONOLISA™ Anti-HBc EIA is a lab test used to detect antibodies associated with hepatitis B (HBV) infection. Antibodies are substances produced by the body to fight against foreign substances called antigens, such as HBV core antigen. Presence of the antibodies can help determine if the patient is currently or has previously been infected with HBV.

How does it work?

  • The MONOLISA™ Anti-HBc EIA is an enzyme immunoassay
  • Patient specimens are incubated with microwells coated with recombinant HBc antigen.
  • If antibodies to HBc are present in a specimen or control, they bind to the antigen
  • The anti-human conjugate is then added to the microwells and allowed to incubate
  • If a sample contains anti-HBc, the bound enzyme (HRP) causes the colorless tetramethylbenzidine,
    solution to change to blue

When is it used? This lab test is used to determine if the person is, or has been, infected with HBV.

What will it accomplish? Results of this lab test may help a doctor determine:

  • the stage of HBV infection
  • an appropriate course of treatment, depending on the stage of HBV infection

When should it not be used? This lab test should not be used if it is not ordered by a physician. This test is a prescription device. This test has not been FDA licensed for screening blood donors. There are no other known patient exclusions.

Additional information: The Summary of Safety and Effectiveness and labeling will be available at:

Page Last Updated: 08/25/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English